Post by mnholdem on Sept 4, 2018 19:15:02 GMT -5
www.latimes.com/business/la-fi-mannkind-hypertension-deal-20180904-story
MannKind strikes deal for inhalable hypertension treatment, sending stock soaring
By JIM PUZZANGH
SEP 4, 2018 - Washington
Excerpt:
Castagna said the stock price has been hurt by the company’s negative cash flow. He said Afrezza sales have improved each quarter since the start of 2017 and the United Therapeutics deal will help MannKind expand TV advertising for the diabetes treatment.
“The more we invest in Afrezza, the faster it grows. … Ninety-nine percent of people with diabetes don’t know inhalable is an option for them,” he said.
MannKind strikes deal for inhalable hypertension treatment, sending stock soaring
By JIM PUZZANGH
SEP 4, 2018 - Washington
Excerpt:
Castagna said the stock price has been hurt by the company’s negative cash flow. He said Afrezza sales have improved each quarter since the start of 2017 and the United Therapeutics deal will help MannKind expand TV advertising for the diabetes treatment.
“The more we invest in Afrezza, the faster it grows. … Ninety-nine percent of people with diabetes don’t know inhalable is an option for them,” he said.
